细菌性角膜炎:识别临床不确定性的领域
细菌性角膜炎是常见角膜感染,用局部抗菌药治疗,但就诊时可能已有严重视力丧失且治疗后持续。高收入与低中收入国家在危险因素和细菌分离株上差异显著,通用管理指南可能不适用。本综述讨论诊断标准、培养阴性病例、药敏估算、耐药性、毒力因子和新技术等多个临床不确定性领域。
要点
- 约50%临床符合细菌性角膜炎的病例培养阴性,其病因未知。
- 当前药敏估算基于全身给药数据而非角膜浓度和生物活性。
- 耐药性增加令人担忧,但对疾病结局的影响尚不清楚。
核心结论
- 本综述呈现了妨碍细菌性角膜炎研究和临床管理的多个临床不确定性领域,并讨论文献中已确立的一些假设和教条。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- 高收入国家与低中收入国家在细菌性角膜炎相关危险因素和细菌分离株上存在显著差异。
- 约50%临床符合细菌性角膜炎的病例培养阴性,其病因未知。
- 当前细菌对抗菌药物敏感性估算基于全身给药数据及可达到的血浆或组织浓度,而非角膜相关浓度和角膜内生物活性。
- 抗菌药物耐药性患病率增加令人担忧,但其对疾病结局的影响尚不清楚。
- 毒力因子未常规评估,尽管其可能影响菌种内细菌的致病性和结局。
关键数值与推荐
- 细菌性角膜炎仅通过培养确认的概念忽略了约50%临床符合但培养阴性的病例。
- 向临床医生提供分离细菌的最低抑菌浓度将是重要进步。
临床怎么用
- 原文未据此给出推荐。
局限性
- 高收入国家与低中收入国家在危险因素和细菌分离株上差异显著,通用管理指南可能不适用。
- 约50%临床符合细菌性角膜炎的病例培养阴性,其病因未知。
- 抗菌药物耐药性增加对疾病结局的影响尚不清楚。
- 毒力因子未常规评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bacterial keratitis is a common corneal infection that is treated with topical antimicrobials. By the time of presentation there may already be severe visual loss from corneal ulceration and opacity, which may persist despite treatment. There are significant differences in the associated risk factors and the bacterial isolates between high income and low- or middle-income countries, so that general management guidelines may not be appropriate. Although the diagnosis of bacterial keratitis may seem intuitive there are multiple uncertainties about the criteria that are used, which impacts the interpretation of investigations and recruitment to clinical studies. Importantly, the concept that bacterial keratitis can only be confirmed by culture ignores the approximately 50% of cases clinically consistent with bacterial keratitis in which investigations are negative. The aetiology of these culture-negative cases is unknown. Currently, the estimation of bacterial susceptibility to antimicrobials is based on data from systemic administration and achievable serum or tissue concentrations, rather than relevant corneal concentrations and biological activity in the cornea. The provision to the clinician of minimum inhibitory concentrations of the antimicrobials for the isolated bacteria would be an important step forward. An increase in the prevalence of antimicrobial resistance is a concern, but the effect this has on disease outcomes is yet unclear. Virulence factors are not routinely assessed although they may affect the pathogenicity of bacteria within species and affect outcomes. New technologies have been developed to detect and kill bacteria, and their application to bacterial keratitis is discussed. In this review we present the multiple areas of clinical uncertainty that hamper research and the clinical management of bacterial keratitis, and we address some of the assumptions and dogma that have become established in the literature.
引用
- Tuft S, Somerville TF, Li JO, et al. Bacterial keratitis: identifying the areas of clinical uncertainty. Prog Retin Eye Res. 2021. PMID: 34915112. doi:10.1016/j.preteyeres.2021.101031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。